1. Definition of COPD
COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients.
Its pulmonary component is characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases. 1

2. Inflammation in COPD 2

3. Pathogenesis of COPD 3

4. indoor/outdoor pollution
Diagnosis of COPD
EXPOSURE TO RISK
FACTORS
SYMPTOMS
cough
tobacco
sputum
occupation
dyspnea
indoor/outdoor pollution
Diagnosis of COPD is based on a history of exposure to risk factors and the presence of airflow limitation that is not fully reversible, with or without the presence of symptoms.
Patients who have chronic cough and sputum production with a history of exposure to risk factors should be tested for airflow limitation, even if they do not have dyspnea.
For the diagnosis and assessment of COPD, spirometry is the gold standard.
Health care workers involved in the diagnosis and management of COPD patients should have access to spirometry. 
SPIROMETRY 4

5. Spirometry: Normal and Patients with COPD5

6. Spirometry “How-To” Resources from GOLD
Spirometry Guide
Spirometry Quick Guide
Spirometry Teaching Slide Set
To help health care professionals understand how to perform & evaluate spirometry.
All resources available at

7. Classification of COPD Severity
by Spirometry
Stage I: Mild FEV1/FVC < 0.70
FEV1 > 80% predicted
Stage II: Moderate FEV1/FVC < 0.70
50% < FEV1 < 80% predicted
Stage III: Severe FEV1/FVC < 0.70
30% < FEV1 < 50% predicted
Stage IV: Very Severe FEV1/FVC < 0.70
FEV1 < 30% predicted or
FEV1 < 50% predicted plus chronic respiratory failure 7

8. Therapy at Each Stage of COPD
I: Mild
II: Moderate
III: Severe
IV: Very Severe
FEV1/FVC < 70%
FEV1 < 30% predicted
or FEV1 < 50% predicted plus chronic respiratory failure
FEV1/FVC < 70%
30% < FEV1 < 50% predicted
FEV1/FVC < 70%
50% < FEV1 < 80%
predicted
FEV1/FVC < 70%
FEV1 > 80% predicted
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation
This provides a summary of the recommended treatment at each stage of COPD.
Add inhaled glucocorticosteroids if repeated exacerbations
Add long term oxygen if chronic respiratory failure. Consider surgical treatments 8

9. Differential Diagnosis: COPD and Asthma
Onset in mid-life
Symptoms slowly progressive
Long smoking history
Dyspnea during exercise
Largely irreversible airflow
limitation
Onset early in life (often childhood)
Symptoms vary from day to day
Symptoms at night/early morning
Allergy, rhinitis, and/or eczema also present
Family history of asthma
Largely reversible airflow limitation 9

10. COPD and Co-morbid Conditions
Common co-morbid conditions in COPD patients:
Cardiovascular disease
Lung cancer
Osteoporosis
Musculoskeletal disorders
Depression/anxiety
Obesity/type II diabetes
Physicians should identify and treat co-morbid conditions that impact on the clinical course of COPD.
Smoking prevention and cessation, weight control, exercise, and rehabilitation have the potential to beneficially affect COPD and co-morbid conditions.

11. Preventing COPD Exacerbations
Prevent respiratory infections: pneumococcal vaccine, annual influenza vaccine.
Avoid air pollution: remain indoors and close windows on bad air pollution days.
Quit smoking and avoid exposure to secondhand smoke.
Understand medication regimen and proper inhaler use.
Patients with severe COPD and repeated exacerbations (3 or more in a year): use inhaled glucocorticosteroids.
Recognize and respond to early signs of exacerbations to minimize impact when exacerbations do occur.

12. Risk Factors for COPD Genes Oxidative stress Exposure to particles
Tobacco smoke
Occupational dusts, organic and inorganic
Indoor air pollution from heating and cooking with biomass in poorly ventilated dwellings
Outdoor air pollution
Lung growth and development
Oxidative stress
Gender
Age
Respiratory infections
Socioeconomic status
Nutrition
Comorbidities 12

13. Brief Strategies to Help the Patient Willing to Quit Smoking
ASK Systematically identify all tobacco users at every visit.
ADVISE Strongly urge all tobacco users to quit.
ASSESS Determine willingness to make a quit attempt.
ASSIST Aid the patient in quitting.
ARRANGE Schedule follow-up contact.
Reduction of total personal exposure to tobacco smoke, occupational dusts and chemicals, and indoor and outdoor air pollutants are important goals to prevent the onset and progression of COPD.
Smoking cessation is the single most effective - and cost effective - intervention to reduce the risk of developing COPD and stop its progression.
Brief tobacco dependence treatment is effective, and every tobacco user should be offered at least this treatment at every visit to a health care provider.
Three types of counseling are especially effective: practical counseling, social support as part of treatment, and social support arranged outside of treatment. 13

14. Lower Respiratory System
Anatomy of the
Lower Respiratory System
Trachea
Main bronchi
Left
Right
Bronchioles
Acinus
Bronchus
rigid because of C-shaped cartilage rings
Alveolus
Acinus
Capillary
Attenuated epithelium
Alveolus
Alveolar space
Capillaries 14

15. Trachea and major bronchi
Anatomy of the Airways
Trachea and major bronchi
Bronchioles
Smooth muscle
Connective tissue
Cartilage
Mucous membrane
Airway mucous membrane
Mucus
Cilia
Secretory cells
Epithelium
Ciliated cells
Basal membrane
Submucosa 15